25 XP   0   0   10

Alphamab Oncology
Buy, Hold or Sell?

Let's analyse Alphamab Oncology together

PenkeI guess you are interested in Alphamab Oncology. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Alphamab Oncology. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Alphamab Oncology

I send you an email if I find something interesting about Alphamab Oncology.

Quick analysis of Alphamab Oncology (30 sec.)










What can you expect buying and holding a share of Alphamab Oncology? (30 sec.)

How much money do you get?

How much money do you get?
HK$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
HK$1.75
Expected worth in 1 year
HK$0.34
How sure are you?
33.3%

+ What do you gain per year?

Total Gains per Share
HK$-1.40
Return On Investment
-32.8%

For what price can you sell your share?

Current Price per Share
HK$4.27
Expected price per share
HK$3.81 - HK$5.45
How sure are you?
50%

1. Valuation of Alphamab Oncology (5 min.)




Live pricePrice per Share (EOD)

HK$4.27

Intrinsic Value Per Share

HK$-6.66 - HK$-4.21

Total Value Per Share

HK$-4.91 - HK$-2.46

2. Growth of Alphamab Oncology (5 min.)




Is Alphamab Oncology growing?

Current yearPrevious yearGrowGrow %
How rich?$215.1m$258.3m-$43.1m-20.1%

How much money is Alphamab Oncology making?

Current yearPrevious yearGrowGrow %
Making money-$41.5m-$52.6m$11m26.6%
Net Profit Margin-195.2%-282.4%--

How much money comes from the company's main activities?

3. Financial Health of Alphamab Oncology (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#241 / 1019

Most Revenue
#228 / 1019

Most Profit
#864 / 1019

Most Efficient
#634 / 1019

What can you expect buying and holding a share of Alphamab Oncology? (5 min.)

Welcome investor! Alphamab Oncology's management wants to use your money to grow the business. In return you get a share of Alphamab Oncology.

What can you expect buying and holding a share of Alphamab Oncology?

First you should know what it really means to hold a share of Alphamab Oncology. And how you can make/lose money.

Speculation

The Price per Share of Alphamab Oncology is HK$4.27. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Alphamab Oncology.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Alphamab Oncology, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is HK$1.75. Based on the TTM, the Book Value Change Per Share is HK$-0.35 per quarter. Based on the YOY, the Book Value Change Per Share is HK$-0.45 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is HK$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Alphamab Oncology.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 HK$% of Price per ShareHK$% of Price per ShareHK$% of Price per ShareHK$% of Price per ShareHK$% of Price per Share
Usd Eps-0.04-1.0%-0.04-1.0%-0.05-1.3%-0.06-1.3%-0.05-1.1%
Usd Book Value Change Per Share-0.04-1.0%-0.04-1.0%-0.06-1.4%0.041.0%0.040.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.04-1.0%-0.04-1.0%-0.06-1.4%0.041.0%0.040.9%
Usd Price Per Share1.38-1.38-1.74-1.40-1.16-
Price to Earnings Ratio-31.99--31.99--31.82--23.35--19.46-
Price-to-Total Gains Ratio-30.81--30.81--30.12--37.83--37.83-
Price to Book Ratio6.18-6.18-6.49-4.84-4.03-
Price-to-Total Gains Ratio-30.81--30.81--30.12--37.83--37.83-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.545279
Number of shares1833
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.040.04
Usd Total Gains Per Share-0.040.04
Gains per Quarter (1833 shares)-82.0480.37
Gains per Year (1833 shares)-328.15321.49
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-328-3380321311
20-656-6660643632
30-984-9940964953
40-1313-1322012861274
50-1641-1650016071595
60-1969-1978019291916
70-2297-2306022502237
80-2625-2634025722558
90-2953-2962028932879
100-3282-3290032153200

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.06.00.00.0%0.06.00.00.0%
Book Value Change Per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%2.04.00.033.3%2.04.00.033.3%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.06.00.0%0.00.06.00.0%
Total Gains per Share0.01.00.00.0%0.03.00.00.0%1.04.00.020.0%2.04.00.033.3%2.04.00.033.3%

Fundamentals of Alphamab Oncology

About Alphamab Oncology

Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of oncology biologics. Its product pipeline includes KN046, a bispecific monoclonal antibody (BsAb) immune checkpoint inhibitor, which is in Phase III clinical trials that targets clinically-validated immune checkpoints, including programmed death ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4); and KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) BsAb that is in Phase II clinical trials for neoadjuvant treatment of HER2-positive breast cancer and I/II clinical trial treatment of heavily pre-treated breast cancers, as well as Phase II clinical trial for HER2-positive solid tumors. The company's product pipeline also comprises KN019, a CTLA-4-based immunosuppressant fusion protein, which is in Phase II clinical trial for auto-immune diseases and oncology treatment-induced immune disorders; and KN035, an injectable PD-L1 inhibitor that is in phase III clinical trials for advanced solid tumors with deficient mismatch repair/microsatellite instability-high solid tumors, and is in Phase III clinical trials for biliary tract cancer. In addition, its product pipeline also includes KN052, a PD-L1/OX40 bispecific antibody, which is in phase I clinical trial for the treatment of advanced solid tumors; and JSKN003, a biparatopic HER2-targeting antibody-drug conjugate that is in phase Ia/Ib clinical trial for the treatment of advanced malignant solid tumors. The company was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.

Fundamental data was last updated by Penke on 2024-03-28 09:21:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Alphamab Oncology.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Alphamab Oncology earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Alphamab Oncology to the Biotechnology industry mean.
  • A Net Profit Margin of -195.2% means that $-1.95 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Alphamab Oncology:

  • The MRQ is -195.2%. The company is making a huge loss. -2
  • The TTM is -195.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-195.2%TTM-195.2%0.0%
TTM-195.2%YOY-282.4%+87.2%
TTM-195.2%5Y-95.5%-99.7%
5Y-95.5%10Y-79.6%-15.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-195.2%-197.2%+2.0%
TTM-195.2%-210.4%+15.2%
YOY-282.4%-279.3%-3.1%
5Y-95.5%-436.8%+341.3%
10Y-79.6%-599.3%+519.7%
1.1.2. Return on Assets

Shows how efficient Alphamab Oncology is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Alphamab Oncology to the Biotechnology industry mean.
  • -14.2% Return on Assets means that Alphamab Oncology generated $-0.14 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Alphamab Oncology:

  • The MRQ is -14.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -14.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.2%TTM-14.2%0.0%
TTM-14.2%YOY-14.1%-0.1%
TTM-14.2%5Y-17.4%+3.2%
5Y-17.4%10Y-25.4%+8.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.2%-13.6%-0.6%
TTM-14.2%-12.9%-1.3%
YOY-14.1%-11.9%-2.2%
5Y-17.4%-14.2%-3.2%
10Y-25.4%-16.2%-9.2%
1.1.3. Return on Equity

Shows how efficient Alphamab Oncology is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Alphamab Oncology to the Biotechnology industry mean.
  • -19.3% Return on Equity means Alphamab Oncology generated $-0.19 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Alphamab Oncology:

  • The MRQ is -19.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -19.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-19.3%TTM-19.3%0.0%
TTM-19.3%YOY-20.4%+1.1%
TTM-19.3%5Y-17.8%-1.6%
5Y-17.8%10Y-52.8%+35.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-19.3%-17.0%-2.3%
TTM-19.3%-16.1%-3.2%
YOY-20.4%-15.4%-5.0%
5Y-17.8%-20.0%+2.2%
10Y-52.8%-21.1%-31.7%

1.2. Operating Efficiency of Alphamab Oncology.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Alphamab Oncology is operating .

  • Measures how much profit Alphamab Oncology makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Alphamab Oncology to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Alphamab Oncology:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-273.4%+273.4%
TTM-5Y-54.7%+54.7%
5Y-54.7%10Y-45.6%-9.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--286.1%+286.1%
TTM--224.4%+224.4%
YOY-273.4%-288.4%+15.0%
5Y-54.7%-475.2%+420.5%
10Y-45.6%-624.7%+579.1%
1.2.2. Operating Ratio

Measures how efficient Alphamab Oncology is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.71 means that the operating costs are $3.71 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Alphamab Oncology:

  • The MRQ is 3.713. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.713. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.713TTM3.7130.000
TTM3.713YOY3.774-0.060
TTM3.7135Y1.497+2.216
5Y1.49710Y1.248+0.250
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7132.997+0.716
TTM3.7133.247+0.466
YOY3.7743.766+0.008
5Y1.4975.675-4.178
10Y1.2487.857-6.609

1.3. Liquidity of Alphamab Oncology.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Alphamab Oncology is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.88 means the company has $3.88 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Alphamab Oncology:

  • The MRQ is 3.883. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.883. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.883TTM3.8830.000
TTM3.883YOY3.321+0.561
TTM3.8835Y6.798-2.916
5Y6.79810Y5.847+0.951
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.8833.930-0.047
TTM3.8834.251-0.368
YOY3.3215.436-2.115
5Y6.7986.045+0.753
10Y5.8476.363-0.516
1.3.2. Quick Ratio

Measures if Alphamab Oncology is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Alphamab Oncology to the Biotechnology industry mean.
  • A Quick Ratio of 4.28 means the company can pay off $4.28 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Alphamab Oncology:

  • The MRQ is 4.279. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.279. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ4.279TTM4.2790.000
TTM4.279YOY4.983-0.704
TTM4.2795Y8.790-4.511
5Y8.79010Y7.460+1.330
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.2793.629+0.650
TTM4.2794.065+0.214
YOY4.9835.397-0.414
5Y8.7905.993+2.797
10Y7.4606.277+1.183

1.4. Solvency of Alphamab Oncology.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Alphamab Oncology assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Alphamab Oncology to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.26 means that Alphamab Oncology assets are financed with 26.4% credit (debt) and the remaining percentage (100% - 26.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Alphamab Oncology:

  • The MRQ is 0.264. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.264. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.264TTM0.2640.000
TTM0.264YOY0.309-0.044
TTM0.2645Y0.437-0.173
5Y0.43710Y0.437+0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2640.332-0.068
TTM0.2640.334-0.070
YOY0.3090.268+0.041
5Y0.4370.366+0.071
10Y0.4370.390+0.047
1.4.2. Debt to Equity Ratio

Measures if Alphamab Oncology is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Alphamab Oncology to the Biotechnology industry mean.
  • A Debt to Equity ratio of 35.9% means that company has $0.36 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Alphamab Oncology:

  • The MRQ is 0.359. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.359. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.359TTM0.3590.000
TTM0.359YOY0.446-0.087
TTM0.3595Y0.229+0.131
5Y0.22910Y0.442-0.214
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3590.381-0.022
TTM0.3590.390-0.031
YOY0.4460.334+0.112
5Y0.2290.434-0.205
10Y0.4420.466-0.024

2. Market Valuation of Alphamab Oncology

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Alphamab Oncology generates.

  • Above 15 is considered overpriced but always compare Alphamab Oncology to the Biotechnology industry mean.
  • A PE ratio of -31.99 means the investor is paying $-31.99 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Alphamab Oncology:

  • The EOD is -12.648. Based on the earnings, the company is expensive. -2
  • The MRQ is -31.991. Based on the earnings, the company is expensive. -2
  • The TTM is -31.991. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-12.648MRQ-31.991+19.343
MRQ-31.991TTM-31.9910.000
TTM-31.991YOY-31.817-0.174
TTM-31.9915Y-23.350-8.642
5Y-23.35010Y-19.458-3.892
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-12.648-2.315-10.333
MRQ-31.991-2.560-29.431
TTM-31.991-2.664-29.327
YOY-31.817-4.122-27.695
5Y-23.350-6.258-17.092
10Y-19.458-6.108-13.350
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Alphamab Oncology:

  • The EOD is -8.858. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -22.405. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -22.405. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.858MRQ-22.405+13.547
MRQ-22.405TTM-22.4050.000
TTM-22.405YOY-25.340+2.935
TTM-22.4055Y-22.473+0.068
5Y-22.47310Y-18.727-3.745
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.858-3.067-5.791
MRQ-22.405-3.251-19.154
TTM-22.405-3.545-18.860
YOY-25.340-5.595-19.745
5Y-22.473-8.315-14.158
10Y-18.727-8.708-10.019
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Alphamab Oncology is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 6.18 means the investor is paying $6.18 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Alphamab Oncology:

  • The EOD is 2.445. Based on the equity, the company is underpriced. +1
  • The MRQ is 6.184. Based on the equity, the company is overpriced. -1
  • The TTM is 6.184. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD2.445MRQ6.184-3.739
MRQ6.184TTM6.1840.000
TTM6.184YOY6.486-0.302
TTM6.1845Y4.841+1.343
5Y4.84110Y4.034+0.807
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.4451.905+0.540
MRQ6.1842.111+4.073
TTM6.1842.095+4.089
YOY6.4862.836+3.650
5Y4.8413.443+1.398
10Y4.0343.794+0.240
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Alphamab Oncology compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.350-0.3500%-0.452+29%0.343-202%0.291-220%
Book Value Per Share--1.7461.7460%2.097-17%1.762-1%1.474+19%
Current Ratio--3.8833.8830%3.321+17%6.798-43%5.847-34%
Debt To Asset Ratio--0.2640.2640%0.309-14%0.437-39%0.437-39%
Debt To Equity Ratio--0.3590.3590%0.446-19%0.229+57%0.442-19%
Dividend Per Share----0%-0%-0%-0%
Eps---0.338-0.3380%-0.427+27%-0.445+32%-0.377+12%
Free Cash Flow Per Share---0.482-0.4820%-0.537+11%-0.428-11%-0.371-23%
Free Cash Flow To Equity Per Share---0.831-0.8310%-0.129-85%0.278-398%0.219-480%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---4.209--------
Intrinsic Value_10Y_min---6.658--------
Intrinsic Value_1Y_max---0.428--------
Intrinsic Value_1Y_min---0.550--------
Intrinsic Value_3Y_max---1.281--------
Intrinsic Value_3Y_min---1.764--------
Intrinsic Value_5Y_max---2.128--------
Intrinsic Value_5Y_min---3.091--------
Market Cap4119884016.640-153%10420315545.60010420315545.6000%13121878835.200-21%10551534333.952-1%8792945278.293+19%
Net Profit Margin---1.952-1.9520%-2.824+45%-0.955-51%-0.796-59%
Operating Margin----0%-2.7340%-0.5470%-0.4560%
Operating Ratio--3.7133.7130%3.774-2%1.497+148%1.248+198%
Pb Ratio2.445-153%6.1846.1840%6.486-5%4.841+28%4.034+53%
Pe Ratio-12.648+60%-31.991-31.9910%-31.817-1%-23.350-27%-19.458-39%
Price Per Share4.270-153%10.80010.8000%13.600-21%10.936-1%9.113+19%
Price To Free Cash Flow Ratio-8.858+60%-22.405-22.4050%-25.340+13%-22.473+0%-18.727-16%
Price To Total Gains Ratio-12.183+60%-30.815-30.8150%-30.117-2%-37.826+23%-37.826+23%
Quick Ratio--4.2794.2790%4.983-14%8.790-51%7.460-43%
Return On Assets---0.142-0.1420%-0.141-1%-0.174+22%-0.254+79%
Return On Equity---0.193-0.1930%-0.204+5%-0.178-8%-0.528+173%
Total Gains Per Share---0.350-0.3500%-0.452+29%0.343-202%0.291-220%
Usd Book Value--215166046.566215166046.5660%258348798.763-17%217143615.136-1%181558749.235+19%
Usd Book Value Change Per Share---0.045-0.0450%-0.058+29%0.044-202%0.037-220%
Usd Book Value Per Share--0.2230.2230%0.268-17%0.225-1%0.188+19%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.043-0.0430%-0.055+27%-0.057+32%-0.048+12%
Usd Free Cash Flow---59391565.243-59391565.2430%-66126934.712+11%-52781814.007-11%-45677228.602-23%
Usd Free Cash Flow Per Share---0.062-0.0620%-0.069+11%-0.055-11%-0.047-23%
Usd Free Cash Flow To Equity Per Share---0.106-0.1060%-0.016-85%0.036-398%0.028-480%
Usd Market Cap526109188.925-153%1330674295.1731330674295.1730%1675663927.255-21%1347430934.446-1%1122859112.038+19%
Usd Price Per Share0.545-153%1.3791.3790%1.737-21%1.397-1%1.164+19%
Usd Profit---41594699.400-41594699.4000%-52665650.900+27%-54872383.520+32%-46430634.550+12%
Usd Revenue--21306106.50021306106.5000%18646881.700+14%7990597.640+167%6658831.367+220%
Usd Total Gains Per Share---0.045-0.0450%-0.058+29%0.044-202%0.037-220%
 EOD+3 -5MRQTTM+0 -0YOY+20 -125Y+9 -2310Y+17 -15

3.2. Fundamental Score

Let's check the fundamental score of Alphamab Oncology based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-12.648
Price to Book Ratio (EOD)Between0-12.445
Net Profit Margin (MRQ)Greater than0-1.952
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than14.279
Current Ratio (MRQ)Greater than13.883
Debt to Asset Ratio (MRQ)Less than10.264
Debt to Equity Ratio (MRQ)Less than10.359
Return on Equity (MRQ)Greater than0.15-0.193
Return on Assets (MRQ)Greater than0.05-0.142
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Alphamab Oncology based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.276
Ma 20Greater thanMa 504.601
Ma 50Greater thanMa 1004.644
Ma 100Greater thanMa 2005.321
OpenGreater thanClose4.260
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets2,117,531
Total Liabilities559,859
Total Stockholder Equity1,557,672
 As reported
Total Liabilities 559,859
Total Stockholder Equity+ 1,557,672
Total Assets = 2,117,531

Assets

Total Assets2,117,531
Total Current Assets1,494,530
Long-term Assets623,001
Total Current Assets
Cash And Cash Equivalents 116,658
Short-term Investments 281,188
Net Receivables 15,490
Inventory 64,636
Total Current Assets  (as reported)1,494,530
Total Current Assets  (calculated)477,972
+/- 1,016,558
Long-term Assets
Property Plant Equipment 599,886
Intangible Assets 21,185
Long-term Assets  (as reported)623,001
Long-term Assets  (calculated)621,071
+/- 1,930

Liabilities & Shareholders' Equity

Total Current Liabilities384,912
Long-term Liabilities174,947
Total Stockholder Equity1,557,672
Total Current Liabilities
Short Long Term Debt 175,000
Accounts payable 7,612
Total Current Liabilities  (as reported)384,912
Total Current Liabilities  (calculated)182,612
+/- 202,300
Long-term Liabilities
Long term Debt Total 155,279
Capital Lease Obligations Min Short Term Debt20,392
Long-term Liabilities  (as reported)174,947
Long-term Liabilities  (calculated)175,671
+/- 724
Total Stockholder Equity
Common Stock13
Retained Earnings -2,168,264
Capital Surplus 3,725,875
Other Stockholders Equity 48
Total Stockholder Equity (as reported)1,557,672
Total Stockholder Equity (calculated)1,557,672
+/-0
Other
Capital Stock13
Cash And Equivalents952,531
Cash and Short Term Investments 1,350,377
Common Stock Shares Outstanding 939,716
Liabilities and Stockholders Equity 2,117,531
Net Invested Capital 1,882,672
Net Working Capital 1,109,618
Property Plant and Equipment Gross 690,037



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-31
> Total Assets 
46,577
826,893
2,854,583
2,639,522
2,705,091
2,117,531
2,117,5312,705,0912,639,5222,854,583826,89346,577
   > Total Current Assets 
11,215
656,103
2,444,468
2,199,228
2,116,549
1,494,530
1,494,5302,116,5492,199,2282,444,468656,10311,215
       Cash And Cash Equivalents 
57
633,712
1,867,866
185,321
803,306
116,658
116,658803,306185,3211,867,866633,71257
       Short-term Investments 
600
0
514,569
1,878,928
1,182,178
281,188
281,1881,182,1781,878,928514,5690600
       Net Receivables 
7,072
15,323
36,115
84,795
7,606
15,490
15,4907,60684,79536,11515,3237,072
       Inventory 
3,486
7,068
25,918
44,321
57,908
64,636
64,63657,90844,32125,9187,0683,486
   > Long-term Assets 
35,362
170,790
410,115
440,294
588,542
623,001
623,001588,542440,294410,115170,79035,362
       Property Plant Equipment 
34,744
132,856
355,956
383,643
522,841
599,886
599,886522,841383,643355,956132,85634,744
       Intangible Assets 
24,730
24,730
22,669
22,175
21,680
21,185
21,18521,68022,17522,66924,73024,730
       Other Assets 
618
37,934
35,811
47,273
58,019
0
058,01947,27335,81137,934618
> Total Liabilities 
20,266
1,093,921
428,658
366,438
834,802
559,859
559,859834,802366,438428,6581,093,92120,266
   > Total Current Liabilities 
10,266
82,800
200,530
329,535
637,260
384,912
384,912637,260329,535200,53082,80010,266
       Short-term Debt 
600
5,090
514,569
188,000
0
0
00188,000514,5695,090600
       Short Long Term Debt 
2,008
5,090
29,537
188,000
449,990
175,000
175,000449,990188,00029,5375,0902,008
       Accounts payable 
1,728
5,856
7,640
5,277
28,481
7,612
7,61228,4815,2777,6405,8561,728
       Other Current Liabilities 
3,102
53,164
117,245
48,505
35,927
0
035,92748,505117,24553,1643,102
   > Long-term Liabilities 
10,000
1,011,121
228,128
36,903
197,542
174,947
174,947197,54236,903228,1281,011,12110,000
       Long term Debt Total 
0
1,001,121
211,345
24,659
173,456
155,279
155,279173,45624,659211,3451,001,1210
       Other Liabilities 
10,000
10,000
16,783
12,244
24,086
0
024,08612,24416,78310,00010,000
> Total Stockholder Equity
13,419
-267,028
2,425,925
2,273,084
1,870,289
1,557,672
1,557,6721,870,2892,273,0842,425,925-267,02813,419
   Common Stock
20,400
7
12
13
13
13
13131312720,400
   Retained Earnings 
-4,175
-147,373
-966,458
2,273,071
1,870,276
-2,168,264
-2,168,2641,870,2762,273,071-966,458-147,373-4,175
   Capital Surplus 
0
0
3,434,420
3,712,749
3,716,758
3,725,875
3,725,8753,716,7583,712,7493,434,42000
   Treasury Stock000000
   Other Stockholders Equity 
-2,806
-119,662
-42,049
2,273,071
1,870,276
48
481,870,2762,273,071-42,049-119,662-2,806



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in HKD. All numbers in thousands.


Latest Income Statement (annual, 2022-12-31)

Gross Profit (+$)
totalRevenue166,845
Cost of Revenue-44,207
Gross Profit122,638122,638
 
Operating Income (+$)
Gross Profit122,638
Operating Expense-575,321
Operating Income-311,516-452,683
 
Operating Expense (+$)
Research Development468,238
Selling General Administrative86,771
Selling And Marketing Expenses-
Operating Expense575,321555,009
 
Net Interest Income (+$)
Interest Income13,084
Interest Expense-96,487
Other Finance Cost-103,063
Net Interest Income19,660
 
Pretax Income (+$)
Operating Income-311,516
Net Interest Income19,660
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-325,722-311,516
EBIT - interestExpense = -96,487
-325,722
-229,235
Interest Expense96,487
Earnings Before Interest and Taxes (EBIT)--229,235
Earnings Before Interest and Taxes (EBITDA)-256,328
 
After tax Income (+$)
Income Before Tax-325,722
Tax Provision-0
Net Income From Continuing Ops-325,722-325,722
Net Income-325,722
Net Income Applicable To Common Shares-325,722
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--19,660
 

Technical Analysis of Alphamab Oncology
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Alphamab Oncology. The general trend of Alphamab Oncology is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Alphamab Oncology's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Alphamab Oncology.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.85 < 4.85 < 5.45.

The bearish price targets are: 4.05 > 3.81.

Tweet this
Alphamab Oncology Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Alphamab Oncology. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Alphamab Oncology Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Alphamab Oncology. The current macd is -0.11265273.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Alphamab Oncology price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Alphamab Oncology. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Alphamab Oncology price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Alphamab Oncology Daily Moving Average Convergence/Divergence (MACD) ChartAlphamab Oncology Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Alphamab Oncology. The current adx is 14.67.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Alphamab Oncology shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Alphamab Oncology Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Alphamab Oncology. The current sar is 4.7805539.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Alphamab Oncology Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Alphamab Oncology. The current rsi is 41.28. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Alphamab Oncology Daily Relative Strength Index (RSI) ChartAlphamab Oncology Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Alphamab Oncology. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Alphamab Oncology price going down in the near term. -2
  • Trending up: The STOCH %K is trending up. +1
Alphamab Oncology Daily Stochastic Oscillator ChartAlphamab Oncology Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Alphamab Oncology. The current cci is -133.28289515.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Alphamab Oncology Daily Commodity Channel Index (CCI) ChartAlphamab Oncology Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Alphamab Oncology. The current cmo is -23.2797239.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Alphamab Oncology Daily Chande Momentum Oscillator (CMO) ChartAlphamab Oncology Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Alphamab Oncology. The current willr is -72.5.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Alphamab Oncology is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Alphamab Oncology Daily Williams %R ChartAlphamab Oncology Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Alphamab Oncology.

Alphamab Oncology Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Alphamab Oncology. The current atr is 0.30009999.

Alphamab Oncology Daily Average True Range (ATR) ChartAlphamab Oncology Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Alphamab Oncology. The current obv is -188,644,295.

Alphamab Oncology Daily On-Balance Volume (OBV) ChartAlphamab Oncology Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Alphamab Oncology. The current mfi is 55.13.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Alphamab Oncology Daily Money Flow Index (MFI) ChartAlphamab Oncology Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Alphamab Oncology.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-22RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-11-24STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-27MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2023-12-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-31MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-28MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-20CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-02CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-11MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside

6.3. Candlestick Patterns

Alphamab Oncology Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Alphamab Oncology based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5041.276
Ma 20Greater thanMa 504.601
Ma 50Greater thanMa 1004.644
Ma 100Greater thanMa 2005.321
OpenGreater thanClose4.260
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Alphamab Oncology with someone you think should read this too:
  • Are you bullish or bearish on Alphamab Oncology? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Alphamab Oncology? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Alphamab Oncology

I send you an email if I find something interesting about Alphamab Oncology.


Comments

How you think about this?

Leave a comment

Stay informed about Alphamab Oncology.

Receive notifications about Alphamab Oncology in your mailbox!